Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy

BACKGROUND: Methyl-aminolevulinate photodynamic therapy (MAL-PDT) is an excellent option for the treatment of basal cell carcinoma (BCC). However, up to 25% of cases are resistant to this treatment modality. OBJECTIVE: The aim of this study was to identify potential biomarkers of BCC response to MAL...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Gracia-Cazaña, Tamara, Mascaraque, Marta, Lucena, Silvia Rocío, Vera-Álvarez, Jesús, González, Salvador, Juarranz, Ángeles, Gilaberte, Yolanda
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6481917/
https://ncbi.nlm.nih.gov/pubmed/31017970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0215537
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars